Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449686 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL7590767 | 0.78 | PSIP1 (0.42) | ALDH1A1MAPTTP53HTTHSD17B10 | |
| SCHEMBL2444252 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAHPGDHSD17B10 | |
| SCHEMBL2976178 | 0.75 | ALDH1A1 (0.69) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL2978401 | 0.73 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL2966537 | 0.72 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL17511740 | 0.71 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL1980247 | 0.70 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL16218976 | 0.70 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNATP53HTT | |
| SCHEMBL28102527 | 0.70 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | ALDH1A1 3205/4885MAPT 2840/4885LMNA 3243/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | ALDH1A1 3470/4885MAPT 2642/4885LMNA 3268/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | ALDH1A1 3470/4885MAPT 2642/4885LMNA 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.